ShK toxin compositions and methods of use
    2.
    发明授权
    ShK toxin compositions and methods of use 失效
    ShK毒素组成及使用方法

    公开(公告)号:US6077680A

    公开(公告)日:2000-06-20

    申请号:US980858

    申请日:1997-11-26

    摘要: Disclosed are methods and compositions comprising DNA segments, and proteins derived from sea anemone species. More particularly, it concerns the novel ShK toxin, ShK toxin analogs, chemically-modified toxin analogs, and nucleic acid segments encoding the ShK toxin from Stichodactyla helianthus. Various methods for making and using these DNA segments, DNA segments encoding synthetically-modified ShK toxins, and native and synthetic ShK peptides are disclosed, such as, for example, the use of DNA segments as diagnostic probes and templates for protein production, and the use of proteins, fusion protein carriers and peptides in various immunological and diagnostic applications.

    摘要翻译: 公开了包含DNA片段的方法和组合物,以及衍生自海葵种类的蛋白质。 更具体地说,它涉及新型的ShK毒素,ShK毒素类似物,化学修饰的毒素类似物,以及编码来自Stichodactyla helianthus的ShK毒素的核酸片段。 公开了制备和使用这些DNA片段的各种方法,编码合成修饰的ShK毒素的DNA片段和天然和合成的ShK肽,例如使用DNA片段作为蛋白质生产的诊断探针和模板,以及 在各种免疫学和诊断应用中使用蛋白质,融合蛋白载体和肽。

    Production intermediate and process for producing pyridine derivative
    4.
    发明授权
    Production intermediate and process for producing pyridine derivative 失效
    制备吡啶衍生物的中间体和方法

    公开(公告)号:US5734059A

    公开(公告)日:1998-03-31

    申请号:US809467

    申请日:1994-03-20

    摘要: This invention relates to: (1) a compound represented by the formula (V), its tautomer and a mixture of the same; (2) a process for producing the compound represented by the above-mentioned formula (V), its tautomer or a mixture of the same, which comprises reacting N-vinylpiperidone represented by the formula (I) with a nicotinate represented by the formula (II), wherein R represents a lower alkyl group, in the presence of a sodium alkoxide; (3) a process for producing a pyridine derivative represented by the formula (III), which comprises producing the compound represented by the formula (V), its tautomer or a mixture of the same by the process as described in the above (2), and then treating the obtained compound with an acid; and (4) a process for producing a pyridine derivative represented by the formula (IV), in which the treatment with an acid as described in the above (3) is followed by another treatment with a base. Thus, the present invention provides industrial processes for producing pyridine derivatives represented by the formulae (III) and (IV) safely, economically, easily and efficiently without using any hazardous reagents. ##STR1##

    摘要翻译: PCT No.PCT / JP95 / 01911 Sec。 371日期1997年3月20日 102(e)1997年3月20日PCT PCT 1995年9月21日PCT公布。 公开号WO96 / 09300 日期:1996年3月28日本发明涉及:(1)由式(V)表示的化合物,其互变异构体及其混合物; (2)由上述式(V)表示的化合物,其互变异构体或其混合物的制备方法,其包括将由式(I)表示的N-乙烯基哌啶酮与式(I)表示的烟酸酯反应, II),其中R表示低级烷基,在醇盐存在下; (3)制备由式(III)表示的吡啶衍生物的方法,其包括通过上述(2)中所述的方法制备由式(V)表示的化合物,其互变异构体或其混合物, 然后用酸处理得到的化合物; 和(4)由式(IV)表示的吡啶衍生物的制造方法,其中用上述(3)所述的酸处理后,用碱进行另外的处理。 因此,本发明提供了在不使用任何有害试剂的情况下安全,经济,容易且有效地生产由式(III)和(IV)表示的吡啶衍生物的工业方法。 (I)(I)))))))))))))))))))))))))))

    Alpha 7 Nicotinic Receptor Selective Ligands
    7.
    发明申请
    Alpha 7 Nicotinic Receptor Selective Ligands 有权
    Alpha 7烟碱受体选择性配体

    公开(公告)号:US20090215705A1

    公开(公告)日:2009-08-27

    申请号:US11921832

    申请日:2006-06-07

    摘要: The invention relates to the design and synthesis of 3-arylidene-anabaseine compounds that exhibit enhanced selectivity toward alpha7 nicotinic receptors. The compounds are expected to be useful in treating a wide variety of conditions, including neurodegenerative conditions such as Alzheimer's Disease, neurodevelopmental diseases such as schizophrenia, and certain peripherally located inflammations mediated by macrophage infiltration.

    摘要翻译: 本发明涉及对α7烟碱受体具有增强的选择性的3-亚芳基 - 酰胺基化合物的设计和合成。 预期这些化合物可用于治疗各种各样的病症,包括神经变性疾病如阿尔茨海默病,神经发育疾病如精神分裂症,以及由巨噬细胞浸润介导的某些外周位置的炎症。

    Alpha 7 nicotinic receptor selective ligands
    8.
    发明授权
    Alpha 7 nicotinic receptor selective ligands 有权
    α7烟碱受体选择性配体

    公开(公告)号:US08093269B2

    公开(公告)日:2012-01-10

    申请号:US11921832

    申请日:2006-06-07

    IPC分类号: C07D401/04 A61K31/44

    摘要: The invention relates to the design and synthesis of 3-arylidene-anabaseine compounds that exhibit enhanced selectivity toward alpha7 nicotinic receptors. The compounds are expected to be useful in treating a wide variety of conditions, including neurodegenerative conditions such as Alzheimer's Disease, neurodevelopmental diseases such as schizophrenia, and certain peripherally located inflammations mediated by macrophage infiltration.

    摘要翻译: 本发明涉及对α7烟碱受体具有增强的选择性的3-亚芳基 - 酰胺基化合物的设计和合成。 预期这些化合物可用于治疗各种各样的病症,包括神经变性疾病如阿尔茨海默病,神经发育疾病如精神分裂症,以及由巨噬细胞浸润介导的某些外周位置的炎症。